RxDoctor Payments Data

Dafer Samara, MD

Critical Care Medicine · Kansas City, MONPI 1760608798

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by GSK at 27.8% of the total.

$923in general payments, 2019–2025

Across 48 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$257
  • Amgen$137
  • AstraZeneca$122
  • United Therapeutics Corporation$101
  • Insmed, Inc.$80
  • AbbVie$46
  • plus $181 from 8 others

What the payments were for

  • Food & beverage$923100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$923 in reported general payments places this provider in the 80th percentile of 208 critical care medicine providers in Missouri.

See all critical care medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$136,971
Medicare patients
409
Services billed
1,256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter116$103,837
Breztri AerosphereBudesonide/Glycopyr/Formoterol70$52,241
Breo ElliptaFluticasone/Vilanterol26$11,957
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$10,942
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$9,263
Albuterol Sulfate HfaAlbuterol Sulfate133$3,278
Ventolin HfaAlbuterol Sulfate27$1,771
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$1,175
Fluticasone Propionate44$717
Prednisone136$442
Montelukast Sodium89$438
Omeprazole22$351
Doxycycline Hyclate38$336
Azithromycin17$57
Pantoprazole Sodium24$54

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$257$125,057162 claims
AstraZenecaBreztri Aerosphere$122$52,24170 claims
Boehringer IngelheimStiolto Respimat$39$10,94216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 208 critical care medicine providers in Missouri.

Other critical care medicine in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →